Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health FMT stool testing Coverage Update | O…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Criteria for laboratory analysis of donor stool prior to fecal microbiota transplant (FMT) and coverage stance on fecal analysis tests proposed for diagnosing intestinal dysbiosis; applies to Oscar Health claims and providers seeking reimbursement guidance.

    Policy Summary
    PayerOscar Health
    PolicyFecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain prior authorization and document medical necessity and donor screening (history, serum and stool testing) for FMT-related services.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8organisms that MEET CRITERIA (culture)
    8organisms that MEET CRITERIA (NAAT)
    5organisms that DO NOT MEET CRITERIA (NAAT)
    14fecal components NOT MEETING CRITERIA
    MDROMDRO testing required
    >=30procedure codes listed

    Coverage Determinations and Criteria

    FMT donor screening and fecal analysis coverage

    Covered prior to donation for FMT when the listed stool tests are performed by culture or NAAT; NAAT for certain organisms is explicitly not acceptable for donor screening.

    Culture-based donor stool testing that MEETS CRITERIA: Prior to donation for a fecal microbiota transplant (FMT), analysis by bacterial culture of the donor fecal sample for the following microorganisms meets criteria: Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae; Vancomycin-resistant Enterococci (VRE); Carbapenem-resistant Enterobacteriaceae (CRE); Methicillin-resistant Staphylococcus aureus (MRSA); Campylobacter; Shigella; Salmonella.

    List from policy III.1

    NAAT-based donor stool testing that MEETS CRITERIA: Prior to donation for an FMT, analysis by nucleic acid amplification testing (NAAT) of the donor fecal sample for the following microorganisms meets criteria: Clostridium difficile; Campylobacter; Salmonella; Shigella; Shiga toxin-producing Escherichia coli; Norovirus; Rotavirus; COVID-19 (SARS-CoV-2).

    List from policy III.2

    NAAT-based donor stool testing that DOES NOT MEET CRITERIA: Prior to donation for an FMT, analysis by NAAT of the donor fecal sample for the following microorganisms DOES NOT MEET CRITERIA: Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae; Vancomycin-resistant Enterococci (VRE); Carbapenem-resistant Enterobacteriaceae (CRE); Methicillin-resistant Staphylococcus aureus (MRSA); any other microorganisms not listed as meeting criteria above.

    List from policy III.3

    Fecal analysis for dysbiosis NOT MEETING CRITERIA: As a diagnostic test for evaluation of intestinal dysbiosis, IBS, malabsorption, or small intestinal bacterial overgrowth (SIBO), fecal analysis of the following components does NOT meet criteria: triglycerides; chymotrypsin; iso-butyrate, iso-valerate, and n-valerate; meat and vegetable fibers; long chain fatty acids; cholesterol; total short chain fatty acids; quantification of Lactobacilli, bifidobacteria, and E. coli and other 'potential pathogens' including Aeromonas, Bacillus cereus, Campylobacter, Citrobacter, Klebsiella, Proteus, Pseudomonas, Salmonella, Shigella, S. aureus, Vibrio; identification and quantitation of fecal yeast (including C. albicans, C. tropicalis, Rhodotorula and Geotrichum); N-butyrate; beta-glucuronidase; pH; short chain fatty acid distribution; fecal secretory IgA.

    List from policy III.4

    Diagnostic stool testing indications

    Covered when used to exclude infectious causes or assess intestinal inflammation in patients with diarrhea or when evaluating suspected IBD.

    Primary indications: Stool testing is recommended to exclude bacterial, viral, or parasitic causes of diarrhea; to test for Clostridium difficile (testing should be carried out within 2 hours of passage when considered); and to obtain stool for microbiological analysis at diagnosis of inflammatory bowel disease (IBD).

    Sources: WGO, ECCO/ESGAR, BSG

    FMT consideration for C. difficile infection

    Covered when recurrence criteria and prior standard-of-care antibiotic therapy have been met.

    FMT for recurrent CDI: Consider fecal microbiota-based therapies for prevention after completion of standard-of-care antibiotics for recurrent Clostridioides difficile infection (for example, after a second recurrence) or in select high‑risk patients; conventional FMT is considered the best treatment for multiply recurrent CDI when performed with rigorous donor screening. FMT should be considered after completion of appropriate antibiotics per guideline recommendations.

    Sources: AGA, ACG

    Tests specifically listed in this policy as DOES NOT MEET CRITERIA are not supported for coverage because there is a lack of published scientific literature demonstrating that these tests are required and beneficial for diagnosis or treatment. Providers should not expect coverage for donor stool NAATs or fecal analyses designated as not meeting criteria unless new, high-quality evidence supporting clinical utility is available.

    Fecal microbiota transplantation (FMT) is not recommended for treatment of functional gastrointestinal symptoms, global irritable bowel syndrome (IBS), ulcerative colitis, Crohn’s disease, or pouchitis outside of a clinical trial setting. Professional society guidance cited in this policy advises that FMT for inflammatory bowel disease remains investigational except when IBD is complicated by recurrent Clostridioides difficile infection.

    The FDA has issued safety communications highlighting the risk of serious adverse events likely due to transmission of pathogenic organisms with fecal microbiota transplantation. Failure to meet recommended donor screening and testing protocols described in this policy may therefore justify exclusion of donor material or denial of coverage for FMT-related services.

    The fecal analysis components enumerated in section III.4 of this policy (for example, triglycerides; chymotrypsin; various short-chain and long-chain fatty acids; quantification of specific bacterial genera and 'potential pathogens'; fecal yeast identification; beta‑glucuronidase; pH; fecal secretory IgA, among others) are considered to NOT MEET CRITERIA when proposed as diagnostic tests for intestinal dysbiosis, IBS, malabsorption, or small intestinal bacterial overgrowth due to insufficient evidence of clinical utility.

    For patients who meet diagnostic criteria for IBS, certain stool tests are unnecessary to confirm the diagnosis. Examples specifically noted in guideline sources and reflected in this policy include faecal ova and parasite testing and faecal occult blood, which are listed among tests that are not required to establish an IBS diagnosis.

    Procedure Codes and Billing

    Applicable CPT/HCPCS Procedure Codesmixed
    82542Column chromatography, includes mass spectrometry, non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen.
    82705Fat or lipids, feces; qualitative.
    82710Fat or lipids, feces; quantitative.
    82715Fat differential, feces, quantitative.
    83986pH; body fluid, not otherwise specified.
    84311Spectrophotometry, analyte not elsewhere specified.
    87045Culture, bacterial; stool, aerobic, with isolation and preliminary examination, Salmonella and Shigella species.
    87046Culture, bacterial; stool, aerobic, additional pathogens, isolation and presumptive identification of isolates, each plate.
    87075Culture, bacterial; any source, except blood, anaerobic with isolation and presumptive identification of isolates.
    87076Culture, bacterial; anaerobic isolate, additional methods required for definitive identification, each isolate.
    1–10 of 18
    1/2
    Bookend testing interval (operational rule)
    Bookend testing intervalNo more than 60 days between pre- and post-donation MDRO tests; post-donation negative results must be confirmed before released stool is used (quarantine acceptable).
    PurposePermits multiple stool donations to be screened collectively by confirming donor remains MDRO-negative across the interval, reducing risk of MDRO transmission via FMT.
    Acceptable sample typesMDRO testing may include stool testing; for MRSA, nasal or peri-rectal swab culture is an acceptable alternative per FDA guidance.

    Provider Responsibilities, Authorization, and Documentation

    Prior Authorization

    Authorization and medical necessity required

    Services must meet authorization and medical necessity guidelines; coverage does not guarantee reimbursement and is dependent on the member's benefit coverage at the time of request. Providers are responsible for submission of accurate documentation of services performed and claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed.

    • Verify member benefits and obtain prior authorization when required.
    • Ensure medical necessity is documented in the request to support approval.
    Prior Authorization

    Procedure codes may require authorization

    Certain fecal laboratory and culture procedure codes listed in the policy may be subject to authorization per payer rules; providers must document medical necessity consistent with applicable guidelines when submitting claims for these codes.

    • Codes referenced in policy include (but are not limited to) 82542, 82705, 82710, 82715, 83986, 84311, 87045, 87046, 87075, 87076, 87077, 87081, 87102, 87106, 87641, 87798, 89160, S3708.

    Background and Scope

    Intestinal dysbiosis refers to an imbalance in the composition, diversity, or metabolic function of the gut microbiome that has been associated with conditions such as IBS, inflammatory bowel disease, celiac disease, and metabolic disorders. Proposed direct (microbial composition) and indirect (metabolite or enzyme) fecal assays have not established standardized normal ranges or demonstrated consistent clinical benefit, limiting their role in routine care. Fecal microbiota transplantation (FMT) is an intervention intended to restore microbial community structure but requires rigorous donor screening (including targeted culture and NAAT panels described in this policy) to mitigate infectious risks and align with professional-society and regulatory safety guidance.

    Key Terms and Definitions

    Dysbiosis
    DefinitionChange in composition, diversity, or metabolites of the microbiome from a healthy pattern to one associated with disease.
    Clinical relevanceAssociated with conditions such as IBS, IBD, celiac disease, obesity, and other chronic GI disorders; proposed as a target for investigational tests and therapies.
    LimitationsDirect and indirect assessments (e.g., bacterial levels, SCFAs, pH, beta-glucuronidase) lack standardized normal ranges and are not established diagnostic criteria.
    Fecal calprotectin
    DefinitionA fecal marker used to detect intestinal inflammation and to help differentiate inflammatory bowel disease (IBD) from functional disorders such as IBS.
    Clinical roleRecommended by guidelines (WGO and others) as a simple, reliable, and readily available test for measuring IBD activity and useful in primary care and follow-up settings.
    Policy Summary
    PayerOscar Health
    PolicyFecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain prior authorization and document medical necessity and donor screening (history, serum and stool testing) for FMT-related services.
    SourceLink
    On This Page
    Coverage Determinations and CriteriaProcedure Codes and BillingProvider Responsibilities, Authorization, and DocumentationBackground and ScopeKey Terms and Definitions
  1. Confirm payer-specific prior authorization requirements for these CPT/HCPCS codes before performing testing.
  2. Prior Authorization

    Prior authorization expectations for FMT

    When seeking approval for FMT-related services, follow professional-society guidance and FDA safety communications and document the indication, prior treatments, and donor screening steps as part of the authorization request.

    • Document prior standard-of-care therapies and the clinical indication for FMT.
    • Include evidence of adherence to society guidelines and relevant FDA safety communications in the prior authorization submission.
    Step Therapy

    Donor screening steps

    Donor screening for FMT must include evaluation of donor history, serum testing, and stool testing prior to transplantation; document these screening steps in the medical record.

    • Capture donor medical history and risk assessment.
    • Record results of required serum and stool laboratory assays before use of donor stool.
    Step Therapy

    FMT after antibiotics for recurrent CDI

    For recurrent C. difficile infection, consider FMT after completion of standard-of-care antibiotics (for example, after a second recurrence); document prior antibiotic therapy and clinical course when requesting FMT.

    • Confirm completion of recommended antibiotic regimens prior to FMT consideration.
    • Document recurrence number and any high-risk features cited by guideline recommendations.
    Documentation Required

    Provider documentation and donor records may be required

    Follow all documentation and coding requirements outlined in the policy and submit supporting records as requested; include donor records when applicable to support medical necessity and safety of FMT.

    • Provide accurate CPT/HCPCS/ICD-10 coding and clinical documentation for services performed.
    • Include donor history and test results in records when reimbursement for FMT-related services is sought.
    Documentation Required

    Required documentation

    Providers must submit accurate documentation of services performed, including appropriate coding per CPT/HCPCS/ICD-10, and may need to provide donor history, serum testing, and stool testing documentation for FMT.

    • Ensure clinical notes and test reports supporting medical necessity are included with prior authorization requests or claim submissions.
    Documentation Required

    Donor screening and quarantine

    Donors should complete a health questionnaire and laboratory screening assays both before and after donation; stool samples may be quarantined until post-donation MDRO tests are confirmed negative (bookend testing within 60 days is acceptable).

    • Maintain donor questionnaire and both pre- and post-donation laboratory results in donor records.
    • Quarantine donated stool until post-donation MDRO testing confirms negative results (bookend testing no more than 60 days apart).
    Documentation Required

    Document donor screening and testing per FDA/society guidance

    Document adherence to FDA and society guidance on donor screening and stool testing for FMT, including screening for transmissible pathogens and following updated COVID-19 related protections.

    • Record specific tests performed to meet FDA/BSG recommendations (including MDRO testing).
    • Include COVID-19–related donor screening or testing performed per FDA updates.
    Denial Risk

    Coding and documentation risk

    Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed and documentation is not accurate; submit complete and correct coding and supporting clinical documentation to reduce risk of denial.

    • Follow industry-standard coding guidelines and payer-specific rules when billing for fecal testing or FMT.
    • Retain and provide requested documentation promptly if a claim is audited.
    Denial Risk

    Donor MDRO exclusion

    Donor stool that tests positive for MDROs (for example ESBL-producing Enterobacteriaceae, VRE, CRE, MRSA) should not be used for FMT and its use would trigger exclusion of that donor stool from transplantation.

    • Do not use donors or stool samples that test positive for the MDROs specified by FDA/BSG guidance.
    • Document MDRO test results and exclude positive donors from the donor pool.
    Note

    FDA safety communication implications

    FDA safety communications about transmission risks of multi-drug resistant organisms and other pathogenic organisms in FMT affect coverage and safety practices; failure to meet FDA-recommended donor screening/testing requirements may provide grounds for claim denial.

    • Incorporate FDA safety recommendations into donor screening and testing protocols.
    • Retain documentation showing compliance with FDA safety communications to support authorization and claims.
    Operational noteRapid fecal calprotectin tests and home tests may be useful; for suspected IBD consider as part of initial stool testing to exclude inflammatory causes of diarrhea.
    MDRO testing (for FMT donors)
    DefinitionLaboratory testing of donor stool (or donor swabs) to detect multidrug-resistant organisms (MDROs) prior to use in fecal microbiota transplantation.
    Examples of MDROsExtended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae; vancomycin-resistant enterococci (VRE); carbapenem-resistant Enterobacteriaceae (CRE); methicillin-resistant Staphylococcus aureus (MRSA).
    Implications of a positive resultDonors and/or stools positive for MDROs should not be used for FMT; positive MDRO testing contraindicates use and would exclude that donor stool from transplantation.
    Fecal Microbiota Transplantation (FMT)
    DefinitionTransfer of stool from a screened donor to a recipient to restore gut microbial community structure.
    Clinical contextUsed primarily for treatment of recurrent Clostridioides difficile infection and discussed in multiple clinical practice guidelines and trials; requires rigorous donor screening.
    Safety considerationsRequires adherence to FDA and professional-society guidance to minimize risk of transmission of pathogenic organisms, including MDRO screening and documented donor evaluation.